

In The United States Patent and Trademark Office

Attuickt IARIAD 385A US

## RECEIVED

DEC 1 3 2002

Group Art Unit: 1632

TECH CENTER 1600/2900

Examiner: Peter Paras, Jr.

Assistant Commissioner of Patents Washington, DC 20231

Clemons et al

09/435.257

November 5, 1999

FK506-Based Regulation of Biological Events

December 3, 2002

## Petition for Extension of Time & Supplemental Response

Sir:

Serial No.

Filed

For

This paper is in response to the October 7, 2002 Office Communication, a response to which was originally due on November 7, 2002. Applicants request a one month extension for responding and authorize the Commissioner to charge the fee due for such extension to Deposit Account No. 01-2315. The new deadline is now December 7, 2002. Accordingly. this response should be considered timely filed.

The Communication noted that our prior Response did not indicate the location in the specification for the genbank accession numbers which are recited in Claims 2 and 3 and further noted that the claims as written rely upon a somewhat awkward reference to cDNA sequences in connection with peptide sequence numbering.

Applicants apologize for those oversights.

The genbank accession numbers recited in the claims are identified in the specification in the table on page 28 in connection with human Calcineurin A and B genes.

The reference in claims 2 and 3 to cDNA sequences is corrected in the attached clean and marked up amended claims. The amendments are formalistic changes and introduce no new matter.

In view of the foregoing, applicants request reconsideration and allowance of their claims. If there are any remaining issues that might be resolvable by phone, applicants' attorney encourages the Examiner to call him at the number provided below.

Respectfully submitted,

ARIAD Pharmaceuticals, Inc. 26 Landsdowne Street

Cambridge, MA 02139 Telephone: 617-494-0400 Ext. 266 Date Tuesday, December 3, 2002

I hereby certify that this paper is being deposited with the US Postai Service via First Class Mail under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner of Patents, Washington, DC 20231

Sue Wilson Signed